DGX Stock: Price, Earnings History and SEC Filings
Quest Diagnostics Incorporated (DGX) last traded at $251.82, down 0.43% on the latest session and up 8.0% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $3.00 against an analyst estimate of $2.85, a beat of 5.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DGX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 22, 2026 | $3.00 | $2.85 | +5.26% |
| Jun 2026 | Jul 23, 2026 | $3.12 | $2.81 | +11.03% |
| Mar 2026 | Apr 21, 2026 | $2.50 | $2.37 | +5.49% |
| Dec 2025 | Feb 10, 2026 | $2.42 | $2.35 | +2.98% |
DGX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How DGX reacts to earnings
Across its last 8 earnings releases, DGX moved 5.2% on average the next session, in either direction. It rose after 7 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-22 | Before open | +1.82% |
| 2026-07-23 | Before open | +8.61% |
| 2026-04-21 | Before open | +4.45% |
| 2026-02-10 | Before open | +7.37% |
| 2026-01-12 | After close | +2.28% |
| 2025-10-21 | Before open | -3.03% |
| 2025-07-22 | Before open | +7.08% |
| 2025-04-22 | Before open | +6.78% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
DGX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $11.0B | $992M | $1.4B | 9.0% | $8.75 |
| 2024 | $9.9B | $871M | $909M | 8.8% | $7.69 |
| 2023 | $9.3B | $854M | $864M | 9.2% | $7.49 |
| 2022 | $9.9B | $946M | $1.3B | 9.6% | $7.97 |
| 2021 | $10.8B | $2.0B | $1.8B | 18.5% | $15.55 |
| 2020 | $9.4B | $1.4B | $1.6B | 15.2% | $10.47 |
| 2019 | $7.7B | $858M | $843M | 11.1% | $6.28 |
| 2018 | $7.5B | $736M | $817M | 9.8% | $5.29 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DGX
- 10-Q · Oct 23, 2026
- 8-K · Oct 22, 2026Other events
- 8-K · Oct 22, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 6, 2026Officer or director change
- 10-Q · Jul 23, 2026
- 8-K · Jul 23, 2026Results of operations, Financial statements and exhibits
- 8-K · May 21, 2026Shareholder vote
- 8-K · May 8, 2026Material agreement, Financial statements and exhibits
- 8-K · May 1, 2026Other events, Financial statements and exhibits
- 424B2 · Apr 28, 2026
Insider filing activity
DGX insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DGX news
- EBay Leads Five Stocks Near Buy Points From Resilient SectorsOct 31, 2026 · finance.yahoo.com
- Labcorp, Quest urge RESULTS Act passage as lab payment cuts loomOct 30, 2026 · medtechdive.com
- Global Genetic Counseling Services Market Report 2026 | Capitalize on AI and Telehealth as Market Hits $4.67 Billion by 2030: Labcorp, Quest Diagnostics, Natera, GeneDxOct 30, 2026 · finance.yahoo.com
- Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and IlluminaOct 30, 2026 · finance.yahoo.com
- Can Hims & Hers Stock Fall 30%?Oct 28, 2026 · trefis.com
- Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?Oct 27, 2026 · finance.yahoo.com
- Hasbro Upgraded, General Motors Downgraded: Updated Rankings on Top Blue-Chip StocksOct 26, 2026 · finance.yahoo.com
- Quest Diagnostics (DGX) Stock Price Stalls After Strong Q3 EarningsOct 24, 2026 · finance.yahoo.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) is a US-listed public company on NYSE. The SEC classifies its business as Services-medical Laboratories. It is incorporated in DE. Its fiscal year ends in December.